E 
59.45
-2.14%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Elekta AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker EKTA B.ST. It has been listed since 1 March 1994. In the fiscal year to 30 April 2026, it reported revenue of SEK 16.72bn and a net loss of SEK 520.0m. At that date it held total assets of SEK 26.95bn and shareholders' equity of SEK 7.10bn.
Elekta AB is a medical technology company. The company is headquartered in Stockholm, Stockholm. The firm offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The firm has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The firm owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Mar 1994
- Employees
- 4,095
- Website
- elekta.com ↗
Leadership
Pay as last reported
- Mr. Laurent LeksellChairman of the Board, since 1972SEK 1.8m
- Mr. Jakob Just-BomholtPresident, Chief Executive Officer, Member of the Executive Committee
- Mr. Tobias HagglovChief Financial Officer, Member of the Executive Committee
- Ms. Anna LundgrenExecutive Vice President, Chief People Officer, Member of the Executive Committee
- Mr. Jonas BolanderMember of the Executive CommitteeSEK 1.7m
- Mr. Christopher BuschPresident - Linac & Software Solutions, Member of the Executive Committee
- Mr. John LaprePresident - Brachy & Neuro Solutions, Member of the Executive Committee, since 2023
- Mr. Habib NehmeChief Commercial Officer, Member of the Executive Committee
- Mr. Jan De WitteDirector
- Ms. Ann CostelloIndependent DirectorSEK 695,000
- Mr. Tomas EliassonIndependent DirectorSEK 1.0m
- Mr. Jan KimpenIndependent DirectorSEK 695,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 94
- Environment
- 99
- Social
- 99
- Governance
- 83
- Direct emissions (scope 1)
- 6,141 t
- Energy emissions (scope 2)
- 5,016 t
- Value chain emissions (scope 3)
- 531,640 t
- Women in the workforce
- 29.82196%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Elekta AB is a leading global provider of innovative radiation oncology and neurosurgery solutions, with a strong focus on cancer treatment.
- The company has a wide range of high-quality products and advanced technologies that have established it as a trusted brand in the medical equipment industry.
- Elekta AB has a strong global presence, with a widespread customer base and strategic partnerships with healthcare institutions and research centers.
- The company invests significantly in research and development, allowing them to stay at the forefront of technological advancements and maintain a competitive edge.
- Elekta AB faces intense competition from other major players in the medical equipment market, which puts pressure on pricing and market share.
- The company heavily relies on a few key products, leaving it vulnerable to market fluctuations and changing customer preferences.
- There may be concerns about the high costs associated with Elekta AB's medical equipment and solutions, which could limit adoption in certain markets and healthcare settings.
- Geopolitical instabilities and regulatory challenges in different regions could potentially hinder the company's operations and growth.
- The increasing prevalence of cancer and neurological disorders globally presents a significant opportunity for Elekta AB to expand its market reach and revenue.
- Technological advancements in radiation oncology and neurosurgery offer opportunities for the development of new cutting-edge products and treatments.
- Elekta AB can explore new emerging markets, particularly in developing countries, where there is a growing demand for improved healthcare infrastructure.
- Strategic collaborations with healthcare providers and research organizations can enhance Elekta AB's product offerings and drive innovation.
- Changes in healthcare policies and regulations, particularly related to reimbursement and pricing, can pose a threat to Elekta AB's profitability and market position.
- Intense competition from both established players and new entrants in the medical equipment market could potentially erode Elekta AB's market share.
- Economic downturns and financial uncertainties may lead to reduced healthcare spending, impacting the demand for Elekta AB's products and services.
- Rapid technological advancements and disruptive innovations can quickly render existing products obsolete, requiring Elekta AB to continuously invest in research and development.
Weaknesses
- Elekta AB faces intense competition from other major players in the medical equipment market, which puts pressure on pricing and market share.
- The company heavily relies on a few key products, leaving it vulnerable to market fluctuations and changing customer preferences.
- There may be concerns about the high costs associated with Elekta AB's medical equipment and solutions, which could limit adoption in certain markets and healthcare settings.
- Geopolitical instabilities and regulatory challenges in different regions could potentially hinder the company's operations and growth.
- The increasing prevalence of cancer and neurological disorders globally presents a significant opportunity for Elekta AB to expand its market reach and revenue.
- Technological advancements in radiation oncology and neurosurgery offer opportunities for the development of new cutting-edge products and treatments.
- Elekta AB can explore new emerging markets, particularly in developing countries, where there is a growing demand for improved healthcare infrastructure.
- Strategic collaborations with healthcare providers and research organizations can enhance Elekta AB's product offerings and drive innovation.
- Changes in healthcare policies and regulations, particularly related to reimbursement and pricing, can pose a threat to Elekta AB's profitability and market position.
- Intense competition from both established players and new entrants in the medical equipment market could potentially erode Elekta AB's market share.
- Economic downturns and financial uncertainties may lead to reduced healthcare spending, impacting the demand for Elekta AB's products and services.
- Rapid technological advancements and disruptive innovations can quickly render existing products obsolete, requiring Elekta AB to continuously invest in research and development.
Opportunities
- The increasing prevalence of cancer and neurological disorders globally presents a significant opportunity for Elekta AB to expand its market reach and revenue.
- Technological advancements in radiation oncology and neurosurgery offer opportunities for the development of new cutting-edge products and treatments.
- Elekta AB can explore new emerging markets, particularly in developing countries, where there is a growing demand for improved healthcare infrastructure.
- Strategic collaborations with healthcare providers and research organizations can enhance Elekta AB's product offerings and drive innovation.
- Changes in healthcare policies and regulations, particularly related to reimbursement and pricing, can pose a threat to Elekta AB's profitability and market position.
- Intense competition from both established players and new entrants in the medical equipment market could potentially erode Elekta AB's market share.
- Economic downturns and financial uncertainties may lead to reduced healthcare spending, impacting the demand for Elekta AB's products and services.
- Rapid technological advancements and disruptive innovations can quickly render existing products obsolete, requiring Elekta AB to continuously invest in research and development.
Threats
- Changes in healthcare policies and regulations, particularly related to reimbursement and pricing, can pose a threat to Elekta AB's profitability and market position.
- Intense competition from both established players and new entrants in the medical equipment market could potentially erode Elekta AB's market share.
- Economic downturns and financial uncertainties may lead to reduced healthcare spending, impacting the demand for Elekta AB's products and services.
- Rapid technological advancements and disruptive innovations can quickly render existing products obsolete, requiring Elekta AB to continuously invest in research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.